GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update

Peter J Hoskin; Alessandro Colombo; Ann Henry; Peter Niehoff; Taran Paulsen Hellebust; Frank-Andre Siebert; Gyorgy Kovacs

doi:10.1016/j.radonc.2013.05.002

GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update

Peter J Hoskin
, Alessandro Colombo
, Ann Henry
, Peter Niehoff
, Taran Paulsen Hellebust
, Frank-Andre Siebert
, Gyorgy Kovacs

Division of Cancer Sciences (L5)

Mount Vernon Cancer Centre

Research output: Contribution to journal › Review article › peer-review

Abstract

BACKGROUND: HDR afterloading brachytherapy (HDRBT) for prostate cancer is now established as an effective technique to achieve dose escalation in the radical treatment of localized prostate cancer. The previous guidelines published in 2005 from GEC ESTRO and EAU have been updated to reflect the current and emerging roles for HDRBT in prostate cancer.

PATIENTS AND METHOD: The indications for HDRBT in dose escalation schedules with external beam are wide ranging with all patients having localized disease eligible for this technique. Exclusion criteria are few encompassing patients medically unfit for the procedure and those with significant urinary outflow symptoms.

RESULTS: Recommendations for patient selection, treatment facility, implant technique, dose prescription and dosimetry reporting are given.

CONCLUSIONS: HDRBT in prostate cancer can be practiced effectively and safely within the context of these guidelines with the main indication being for dose escalation with external beam. HDRBT used alone is currently under evaluation and its role in focal treatment and recurrence will be areas of future development.

Original language	English
Pages (from-to)	325-32
Number of pages	8
Journal	Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Volume	107
Issue number	3
DOIs	https://doi.org/10.1016/j.radonc.2013.05.002
Publication status	Published - Jun 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Brachytherapy/methods
Humans
Male
Neoplasm Staging
Practice Guidelines as Topic
Prostatic Neoplasms/diagnostic imaging
Radiotherapy Dosage
Ultrasonography

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

Access to Document

10.1016/j.radonc.2013.05.002

GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: An update.
Hoskin, P. (Participant), Colombo, A. (Participant), Henry, A. (Participant), Niehoff, P. (Participant), Paulsen Hellebust, T. (Participant), Siebert, F.-A. (Participant) & Kovacs, G. (Participant)
Impact

Cite this

Hoskin, P. J., Colombo, A., Henry, A., Niehoff, P., Paulsen Hellebust, T., Siebert, F.-A., & Kovacs, G. (2013). GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 107(3), 325-32. https://doi.org/10.1016/j.radonc.2013.05.002

@article{c6a03ad2708641599cfa024792043848,

title = "GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update",

abstract = "BACKGROUND: HDR afterloading brachytherapy (HDRBT) for prostate cancer is now established as an effective technique to achieve dose escalation in the radical treatment of localized prostate cancer. The previous guidelines published in 2005 from GEC ESTRO and EAU have been updated to reflect the current and emerging roles for HDRBT in prostate cancer.PATIENTS AND METHOD: The indications for HDRBT in dose escalation schedules with external beam are wide ranging with all patients having localized disease eligible for this technique. Exclusion criteria are few encompassing patients medically unfit for the procedure and those with significant urinary outflow symptoms.RESULTS: Recommendations for patient selection, treatment facility, implant technique, dose prescription and dosimetry reporting are given.CONCLUSIONS: HDRBT in prostate cancer can be practiced effectively and safely within the context of these guidelines with the main indication being for dose escalation with external beam. HDRBT used alone is currently under evaluation and its role in focal treatment and recurrence will be areas of future development.",

keywords = "Brachytherapy/methods, Humans, Male, Neoplasm Staging, Practice Guidelines as Topic, Prostatic Neoplasms/diagnostic imaging, Radiotherapy Dosage, Ultrasonography",

author = "Hoskin, \{Peter J\} and Alessandro Colombo and Ann Henry and Peter Niehoff and \{Paulsen Hellebust\}, Taran and Frank-Andre Siebert and Gyorgy Kovacs",

year = "2013",

month = jun,

doi = "10.1016/j.radonc.2013.05.002",

language = "English",

volume = "107",

pages = "325--32",

journal = "Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology",

issn = "0167-8140",

publisher = "Elsevier BV",

number = "3",

}

Hoskin, PJ, Colombo, A, Henry, A, Niehoff, P, Paulsen Hellebust, T, Siebert, F-A & Kovacs, G 2013, 'GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update', Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, vol. 107, no. 3, pp. 325-32. https://doi.org/10.1016/j.radonc.2013.05.002

GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. / Hoskin, Peter J; Colombo, Alessandro; Henry, Ann et al.
In: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, Vol. 107, No. 3, 06.2013, p. 325-32.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer

T2 - an update

AU - Hoskin, Peter J

AU - Colombo, Alessandro

AU - Henry, Ann

AU - Niehoff, Peter

AU - Paulsen Hellebust, Taran

AU - Siebert, Frank-Andre

AU - Kovacs, Gyorgy

PY - 2013/6

Y1 - 2013/6

N2 - BACKGROUND: HDR afterloading brachytherapy (HDRBT) for prostate cancer is now established as an effective technique to achieve dose escalation in the radical treatment of localized prostate cancer. The previous guidelines published in 2005 from GEC ESTRO and EAU have been updated to reflect the current and emerging roles for HDRBT in prostate cancer.PATIENTS AND METHOD: The indications for HDRBT in dose escalation schedules with external beam are wide ranging with all patients having localized disease eligible for this technique. Exclusion criteria are few encompassing patients medically unfit for the procedure and those with significant urinary outflow symptoms.RESULTS: Recommendations for patient selection, treatment facility, implant technique, dose prescription and dosimetry reporting are given.CONCLUSIONS: HDRBT in prostate cancer can be practiced effectively and safely within the context of these guidelines with the main indication being for dose escalation with external beam. HDRBT used alone is currently under evaluation and its role in focal treatment and recurrence will be areas of future development.

AB - BACKGROUND: HDR afterloading brachytherapy (HDRBT) for prostate cancer is now established as an effective technique to achieve dose escalation in the radical treatment of localized prostate cancer. The previous guidelines published in 2005 from GEC ESTRO and EAU have been updated to reflect the current and emerging roles for HDRBT in prostate cancer.PATIENTS AND METHOD: The indications for HDRBT in dose escalation schedules with external beam are wide ranging with all patients having localized disease eligible for this technique. Exclusion criteria are few encompassing patients medically unfit for the procedure and those with significant urinary outflow symptoms.RESULTS: Recommendations for patient selection, treatment facility, implant technique, dose prescription and dosimetry reporting are given.CONCLUSIONS: HDRBT in prostate cancer can be practiced effectively and safely within the context of these guidelines with the main indication being for dose escalation with external beam. HDRBT used alone is currently under evaluation and its role in focal treatment and recurrence will be areas of future development.

KW - Brachytherapy/methods

KW - Humans

KW - Male

KW - Neoplasm Staging

KW - Practice Guidelines as Topic

KW - Prostatic Neoplasms/diagnostic imaging

KW - Radiotherapy Dosage

KW - Ultrasonography

U2 - 10.1016/j.radonc.2013.05.002

DO - 10.1016/j.radonc.2013.05.002

M3 - Review article

C2 - 23773409

SN - 0167-8140

VL - 107

SP - 325

EP - 332

JO - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

JF - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

IS - 3

ER -

GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update

Abstract

UN SDGs

Keywords

Research Beacons, Institutes and Platforms

Access to Document

Fingerprint

Impacts

GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: An update.

Cite this